Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H24N8O4S.CH4O3S |
| Molecular Weight | 604.659 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.COC1=CC=C(C=N1)C2=NC3=C(SC(CN(C)C4=NC=C(C=N4)C(=O)NO)=C3)C(=N2)N5CCOCC5
InChI
InChIKey=CFLAKAHRZMPILU-UHFFFAOYSA-N
InChI=1S/C23H24N8O4S.CH4O3S/c1-30(23-25-11-15(12-26-23)22(32)29-33)13-16-9-17-19(36-16)21(31-5-7-35-8-6-31)28-20(27-17)14-3-4-18(34-2)24-10-14;1-5(2,3)4/h3-4,9-12,33H,5-8,13H2,1-2H3,(H,29,32);1H3,(H,2,3,4)
| Molecular Formula | CH4O3S |
| Molecular Weight | 96.106 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C23H24N8O4S |
| Molecular Weight | 508.553 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22693356
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22693356
CUDC-907 is a small molecule inhibitor of histone deacetylase and PI3 kinase developed by Curis. It is investigated in clinical trials for the treatment of relapsed or refractory lymphomas, thyroid cancer, multiple myeloma, breast cancer and other malignancies.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL325 |
1.7 nM [IC50] | ||
Target ID: CHEMBL1829 |
1.8 nM [IC50] | ||
Target ID: CHEMBL5103 |
2.8 nM [IC50] | ||
Target ID: P42336 Gene ID: 5290.0 Gene Symbol: PIK3CA Target Organism: Homo sapiens (Human) |
19.0 nM [IC50] | ||
Target ID: O00329 Gene ID: 5293.0 Gene Symbol: PIK3CD Target Organism: Homo sapiens (Human) |
39.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
9.19 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28860342 |
60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CUDC-907 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
24.5 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28860342 |
60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CUDC-907 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.89 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/28860342 |
60 mg 1 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CUDC-907 plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Sample Use Guides
The recommended dose for phase 2 clinical trial is 60 mg on the 5/2 dosing schedule.
Route of Administration:
Oral
Human cancer cell lines were purchased from American Type Culture Collection (Manassas, VA) and plated at densities of 5,000 to 10,000 per well in 96-well flat-bottomed plates with the recommended culture medium. The cells were then incubated with compounds at various concentrations for 72 hours in culture medium supplemented with 0.5% (v/v) FBS. Growth inhibition was assessed by assay of cellular ATP content using the Perkin-Elmer ATPlite kit. CUDC-907 inhibits the growth of cell lines with IC50 of 10-100 nM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:42:53 GMT 2025
by
admin
on
Mon Mar 31 19:42:53 GMT 2025
|
| Record UNII |
B618F4630I
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
B618F4630I
Created by
admin on Mon Mar 31 19:42:53 GMT 2025 , Edited by admin on Mon Mar 31 19:42:53 GMT 2025
|
PRIMARY | |||
|
1401998-36-4
Created by
admin on Mon Mar 31 19:42:53 GMT 2025 , Edited by admin on Mon Mar 31 19:42:53 GMT 2025
|
PRIMARY | |||
|
300000042359
Created by
admin on Mon Mar 31 19:42:53 GMT 2025 , Edited by admin on Mon Mar 31 19:42:53 GMT 2025
|
PRIMARY | |||
|
88962004
Created by
admin on Mon Mar 31 19:42:53 GMT 2025 , Edited by admin on Mon Mar 31 19:42:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |